Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

False-positive results with select HIV-1 NAT methods following lentivirus-based tisagenlecleucel therapy

Theodore W. Laetsch, Shannon L. Maude, Michael C. Milone, Kara L. Davis, Joerg Krueger, Ana Maria Cardenas, Lamis K. Eldjerou, Christopher H. Keir, Patricia A. Wood, Stephan A. Grupp

Blood (2018) 131 (23): 2596–2598.

https://doi.org/10.1182/blood-2017-12-822940

Published: 2018

Journal Articles

Pharmacokinetics and Pharmacodynamics of Tocilizumab for the Management of Cytokine Release Syndrome (CRS) in Pediatric and Young Adult Patients with Relapsed/Refractory (R/R) B-Cell Acute Lymphoblastic Leukemia (B-ALL) Treated with CAR T-Cell Therapy, CTL019

Clarice Lee, PharmD, Henrique Bittencourt, MD PhD, Susana Rives, MD PhD, Michael W Boyer, MD, Michael A Pulsipher, MD, Michael R Verneris, MD, Gregory Yanik, MD, Birgit Jaitner, PhD, Lan Yi, PhD, Kathryn Lund, BS, Mimi Leung, MPH, Rakesh Awasthi, PhD, Patricia A Wood, MD PhD, Shannon L Maude, MD PhD, Stephan A Grupp, MD PhD, Karen Thudium Mueller, PharmD,MSc

Blood (2017) 130 (Supplement 1): 2553.

https://doi.org/10.1182/blood.V130.Suppl_1.2553.2553

Published: 2017

Journal Articles

CTL019 Model-Based Cellular Kinetic Analysis of Chimeric Antigen Receptor (CAR) T Cells to Characterize the Impact of Tocilizumab on Expansion and to Identify Correlates of Cytokine Release Syndrome Severity

Andrew M Stein, Stephan A Grupp, MD PhD, John E Levine, MD, Theodore W Laetsch, MD, Michael A Pulsipher, MD, Michael W Boyer, MD, Keith J August, MD MS, Bruce L Levine, PhD, Carl H June, MD, Lori Tomassian, MS, Sweta Shah, PharmD, Mimi Leung, MPH, Pai-Hsi Huang, Sebastien Jolivet, Rakesh Awasthi, PhD, Karen Thudium Mueller, PharmD,MSc, Patricia A Wood, MD PhD, Shannon L Maude, MD PhD

Blood (2017) 130 (Supplement 1): 2561.

https://doi.org/10.1182/blood.V130.Suppl_1.2561.2561

Published: 2017

Journal Articles

Management of Coagulopathy Associated with CTL019 CAR T-Cell Therapy

Jochen Büchner, MDPhD, Stephan A Grupp, MD PhD, Shannon L Maude, MD PhD, Hidefumi Hiramatsu, MD PhD, David T Teachey, MD, Patricia A Wood, MD PhD, Rakesh Awasthi, PhD, Lan Yi, PhD, Barbara De Moerloose, MD PhD

Blood (2017) 130 (Supplement 1): 1276.

https://doi.org/10.1182/blood.V130.Suppl_1.1276.1276

Published: 2017

Journal Articles

CTL019 Therapy Appears Safe and Effective in Pediatric Patients with Down Syndrome with Relapsed/ Refractory (r/r) Acute Lymphoblastic Leukemia

Theodore W Laetsch, MD, Shannon L Maude, MD PhD, Stephan A Grupp, MD PhD, Michael W Boyer, MD, Andrew C Harris, MD, Muna Qayed, MDMSc, Christine L Phillips, MD, Michael A Pulsipher, MD, Henrique Bittencourt, MD PhD, Patricia A Wood, MD PhD, Karen Thudium Mueller, PharmD,MSc, Yanqui Weng, PhD, Carl H June, MD, Bruce L Levine, PhD, Hidefumi Hiramatsu, MD PhD

Blood (2017) 130 (Supplement 1): 1280.

https://doi.org/10.1182/blood.V130.Suppl_1.1280.1280

Published: 2017

Journal Articles

Impact of Humoral Immunogenicity (Anti-mCAR19 Antibodies) on CTL019 Cellular Kinetics, Efficacy, and Safety

Karen Thudium Mueller, PharmD,MSc, Edward Waldron, PhD, Denise Sickert, PhD, Stephan A Grupp, MD PhD, Shannon L Maude, MD PhD, John E Levine, MD, Theodore W Laetsch, MD, Michael A Pulsipher, MD, Michael W Boyer, MD, Keith J August, MD MS, Rakesh Awasthi, PhD, Bruce L Levine, PhD, Carl H June, MD, Tetiana Taran, MD, Patricia A Wood, MD PhD, Gary Douglas Myers, MD

Blood (2017) 130 (Supplement 1): 1281.

https://doi.org/10.1182/blood.V130.Suppl_1.1281.1281

Published: 2017

Journal Articles

Analysis of a Global Registration Trial of the Efficacy and Safety of CTL019 in Pediatric and Young Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL)

Blood (2016) 128 (22): 221.

https://doi.org/10.1182/blood.V128.22.221.221

Published: 2016

Journal Articles

Cellular Kinetics of Chimeric Antigen Receptor T Cells (CTL019) in Patients with Relapsed/Refractory CD19+ Leukemia

Karen Thudium Mueller, PharmD, MS, Abhijit Chakraborty, PhD, Patricia A Wood, MD PhD, Rakesh Awasthi, BPharm, Alfonso Quintas-Cardama, MD, Xia Han, MS, Shannon L Maude, MD PhD, Stephan A. Grupp, MD PhD, David L Porter, MD, Noelle Frey, MD MS, Katherine T. Marcucci, PhD, Bruce L Levine, PhD, Jan J. Melenhorst, PhD, Carl H June, MD, Simon F. Lacey, PhD

Blood (2016) 128 (22): 220.

https://doi.org/10.1182/blood.V128.22.220.220

Published: 2016

Journal Articles

Efficacy and Safety of CTL019 in the First US Phase II Multicenter Trial in Pediatric Relapsed/Refractory Acute Lymphoblastic Leukemia: Results of an Interim Analysis

Shannon L Maude, MD PhD, Michael A Pulsipher, MD, Michael W Boyer, MD, Stephan A Grupp, MD PhD, Stella M Davies, MBBS, PhD, Christine L Phillips, MD, Michael R Verneris, MD, Keith J August, MD MS, Krysta Schlis, MD, Timothy A Driscoll, MD, Rajen Mody, MD MS, Christian M Capitini, MD, Carl H June, MD, Bruce L Levine, PhD, Patricia A Wood, MD PhD, Lan Yi, PhD, John E Levine, MD MS

Blood (2016) 128 (22): 2801.

https://doi.org/10.1182/blood.V128.22.2801.2801

Published: 2016

Journal Articles

Successful Translation of Chimeric Antigen Receptor (CAR) Targeting CD19 (CTL019) Cell Processing Technology from Academia to Industry

Jeffrey A. Boyd, MBA, Bruce L. Levine, PhD, Kathrin Jinivizian, BS, Margit A. Jeschke, PhD, Megan M. Suhoski Davis, PhD, Zhaohui Zheng, MS, Daniel Stark, PhD, Liza Loidolt, MS, MBA, Christopher H. Keir, MD MS, Patricia A. Wood, MD PhD

Blood (2015) 126 (23): 3100.

https://doi.org/10.1182/blood.V126.23.3100.3100

Published: 2015

Journal Articles

Durable Remissions in Children with Relapsed/Refractory ALL Treated with T Cells Engineered with a CD19-Targeted Chimeric Antigen Receptor (CTL019)

Stephan A. Grupp, MD PhD, Shannon L Maude, MD PhD, Pamela A Shaw, PhD, Richard Aplenc, MD PhD, David M. Barrett, MD PhD, Colleen Callahan, MSN, Simon F. Lacey, PhD BS, Bruce L. Levine, PhD, J Joseph Melenhorst, PhD, Laura Motley, RN, Susan R. Rheingold, MD, David T Teachey, MD, Patricia A. Wood, MD PhD, David Porter, MD, Carl H. June, MD

Blood (2015) 126 (23): 681.

https://doi.org/10.1182/blood.V126.23.681.681

Published: 2015

Journal Articles

Randomized, Phase II Dose Optimization Study of Chimeric Antigen Receptor Modified T Cells Directed Against CD19 (CTL019) in Patients with Relapsed, Refractory CLL

Blood (2014) 124 (21): 1982.

https://doi.org/10.1182/blood.V124.21.1982.1982

Published: 2014

Journal Articles

Cytokine Release Syndrome (CRS) after Chimeric Antigen Receptor (CAR) T Cell Therapy for Relapsed/Refractory (R/R) CLL

Blood (2014) 124 (21): 1983.

https://doi.org/10.1182/blood.V124.21.1983.1983

Published: 2014

Journal Articles

T Cells Engineered with a Chimeric Antigen Receptor (CAR) Targeting CD19 (CTL019) Have Long Term Persistence and Induce Durable Remissions in Children with Relapsed, Refractory ALL

Stephan A. Grupp, MD PhD, Shannon L Maude, MD PhD, Pamela Shaw, PhD, Richard Aplenc, MD PhD, David M. Barrett, MDPhD, Colleen Callahan, MSN, CRNP, Anne Chew, PhD, Simon F. Lacey, PhD BSc, Bruce L. Levine, PhD, J. Joseph Melenhorst, PhD, Laura Motley, RN, BSN, Susan R. Rheingold, MD, Angela Shen, MD, David T. Teachey, MD, Patricia A. Wood, MD PhD, David L Porter, MD, Carl H. June, MD

Blood (2014) 124 (21): 380.

https://doi.org/10.1182/blood.V124.21.380.380

Published: 2014

Journal Articles

Randomized, Phase II Dose Optimization Study Of Chimeric Antigen Receptor Modified T Cells Directed Against CD19 (CTL019) In Patients With Relapsed, Refractory CLL

David L. Porter, MD, Michael Kalos, PhD, Noelle V. Frey, MD, Stephan A Grupp, MD, PhD, Alison W. Loren, MD, Christina Jemision, RN, Joan Gilmore, Holly McConville, RN, BSN, James Capobianchi, Lester Lledo, CRNP, Anne Chew, PhD, Angela Shen, MD, Patricia A. Wood, MD, PhD, Manuel Litchman, MD, Zhaohui Zheng, Bruce L. Levine, PhD, Carl H. June, MD

Blood (2013) 122 (21): 873.

https://doi.org/10.1182/blood.V122.21.873.873

Published: 2013

Journal Articles

T Cells Engineered With a Chimeric Antigen Receptor (CAR) Targeting CD19 (CTL019) Produce Significant In Vivo Proliferation, Complete Responses and Long-Term Persistence Without Gvhd In Children and Adults With Relapsed, Refractory ALL

Stephan A Grupp, MD, PhD, Noelle V. Frey, MD, Richard Aplenc, MD, PhD, David M Barrett, MD/PhD, Anne Chew, PhD, Michael Kalos, PhD, Bruce L. Levine, PhD, Manuel Litchman, MD, Shannon L Maude, MD, PhD, Susan R. Rheingold, Angela Shen, MD, Christine Strait, David T. Teachey, MD, Patricia A. Wood, MD, PhD, David Porter, MD, Carl H. June, MD

Blood (2013) 122 (21): 67.

https://doi.org/10.1182/blood.V122.21.67.67

Published: 2013

NARROW

False-positive results with select HIV-1 NAT methods following lentivirus-based tisagenlecleucel therapy

Pharmacokinetics and Pharmacodynamics of Tocilizumab for the Management of Cytokine Release Syndrome (CRS) in Pediatric and Young Adult Patients with Relapsed/Refractory (R/R) B-Cell Acute Lymphoblastic Leukemia (B-ALL) Treated with CAR T-Cell Therapy, CTL019

CTL019 Model-Based Cellular Kinetic Analysis of Chimeric Antigen Receptor (CAR) T Cells to Characterize the Impact of Tocilizumab on Expansion and to Identify Correlates of Cytokine Release Syndrome Severity

Management of Coagulopathy Associated with CTL019 CAR T-Cell Therapy

CTL019 Therapy Appears Safe and Effective in Pediatric Patients with Down Syndrome with Relapsed/ Refractory (r/r) Acute Lymphoblastic Leukemia

Impact of Humoral Immunogenicity (Anti-mCAR19 Antibodies) on CTL019 Cellular Kinetics, Efficacy, and Safety

Analysis of a Global Registration Trial of the Efficacy and Safety of CTL019 in Pediatric and Young Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL)

Cellular Kinetics of Chimeric Antigen Receptor T Cells (CTL019) in Patients with Relapsed/Refractory CD19+ Leukemia

Efficacy and Safety of CTL019 in the First US Phase II Multicenter Trial in Pediatric Relapsed/Refractory Acute Lymphoblastic Leukemia: Results of an Interim Analysis

Successful Translation of Chimeric Antigen Receptor (CAR) Targeting CD19 (CTL019) Cell Processing Technology from Academia to Industry

Durable Remissions in Children with Relapsed/Refractory ALL Treated with T Cells Engineered with a CD19-Targeted Chimeric Antigen Receptor (CTL019)

Randomized, Phase II Dose Optimization Study of Chimeric Antigen Receptor Modified T Cells Directed Against CD19 (CTL019) in Patients with Relapsed, Refractory CLL

Cytokine Release Syndrome (CRS) after Chimeric Antigen Receptor (CAR) T Cell Therapy for Relapsed/Refractory (R/R) CLL

T Cells Engineered with a Chimeric Antigen Receptor (CAR) Targeting CD19 (CTL019) Have Long Term Persistence and Induce Durable Remissions in Children with Relapsed, Refractory ALL

Randomized, Phase II Dose Optimization Study Of Chimeric Antigen Receptor Modified T Cells Directed Against CD19 (CTL019) In Patients With Relapsed, Refractory CLL

T Cells Engineered With a Chimeric Antigen Receptor (CAR) Targeting CD19 (CTL019) Produce Significant In Vivo Proliferation, Complete Responses and Long-Term Persistence Without Gvhd In Children and Adults With Relapsed, Refractory ALL

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only